Rheumatoid Arthritis Treatment Guidelines

Initial Treatment and Dosing

• The American College of Rheumatology recommends starting methotrexate at 15 mg/week orally, escalating rapidly by 5 mg/month to reach 25-30 mg/week within 8-12 weeks, and switching to subcutaneous administration if inadequate response occurs at maximal tolerated oral dose 1, 2
• The initial methotrexate dose should be 15 mg/week orally, not less than 10 mg/week, as lower starting doses demonstrate inferior clinical efficacy 1, 2, 3

Dose Escalation and Route of Administration

• Methotrexate should be escalated by 5 mg every 4-8 weeks, preferably monthly, until reaching 25-30 mg/week or the maximum tolerated dose, with fast escalation achieving superior clinical effect sizes 1, 2, 3
• Switching from oral to subcutaneous methotrexate when inadequate response occurs at 20-25 mg/week oral dosing, maintaining the same dose, is recommended 1, 2

Combination Therapy and Biologics

• If inadequate response persists after optimizing methotrexate, adding sulfasalazine and hydroxychloroquine (triple therapy) before initiating biologics is recommended 4
• After inadequate response to optimized methotrexate plus triple DMARD therapy, initiating anti-TNF biologics or alternative mechanism biologics while maintaining methotrexate is recommended 4, 6

Monitoring and Supplementation

• Disease activity assessment every 4-6 weeks during dose escalation using validated measures (DAS28, CDAI, or SDAI) is recommended 4, 6
• Prescribing folic acid 5 mg once weekly to all patients to reduce gastrointestinal and hepatic toxicity without compromising efficacy is recommended 5